RT @Sociedad_SEMI: 🩸🩸🩸Recomendaciones de expertos sobre el manejo del sangrado en pacientes anticoagulados ⤵️ @GT_Trombo @mablancom25 https…
🩸🩸🩸Recomendaciones de expertos sobre el manejo del sangrado en pacientes anticoagulados ⤵️ @GT_Trombo @mablancom25
RT @GT_Trombo: Recomendaciones de expertos sobre el manejo del sangrado en pacientes anticoagulados https://t.co/Qhezd0caAP @SEMITuit @S…
Recomendaciones de expertos sobre el manejo del sangrado en pacientes anticoagulados https://t.co/Qhezd0caAP @SEMITuit @Sociedad_SEMI @SemiUrgencias @JACCJournals
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @SnayCardsPharmD: Updated consensus statement on managing bleeding in patients taking DOACs or Warfarin. 2020 ACC Expert Consensus Dec…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @melmack2k: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the Ame…
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding i... https://t.co/GWb76wGZC6
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @jsenior64: Manejo del sangrado en pacientes con anticoagulación oral. @JACCJournals https://t.co/W3AGgXEz7w
RT @jsenior64: Manejo del sangrado en pacientes con anticoagulación oral. @JACCJournals https://t.co/W3AGgXEz7w
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee - ScienceDirect https://t.co/CwySWvdnHh
RT @jsenior64: Manejo del sangrado en pacientes con anticoagulación oral. @JACCJournals https://t.co/W3AGgXEz7w
Manejo del sangrado en pacientes con anticoagulación oral. @JACCJournals https://t.co/W3AGgXEz7w
RT @majedalhoriby: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants link : https:/…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @EDPharmDRoy: Release the tax returns https://t.co/ezUV6JDc66
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @rincondesisifo: (JACC) Abordaje de la hemorragia en pac anticoagulados https://t.co/HezhmzYZQF Consenso de expertos https://t.co/k6RSuM…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @SnayCardsPharmD: Updated consensus statement on managing bleeding in patients taking DOACs or Warfarin. 2020 ACC Expert Consensus Dec…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
SMH.
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @majedalhoriby: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants link : https:/…
For those having to manage bleeding in patients on #anticoagulation, the ACC @ACCinTouch has updated their expert consensus pathway: https://t.co/I9rykSb7ji
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @majedalhoriby: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants link : https:/…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @majedalhoriby: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants link : https:/…
RT @MayaHolsen: Reverse, reverse! ⏮‼️🆘🛑 New guidance: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on…
RT @EDPharmDRoy: Release the tax returns
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @WorldMedicineN1: Consenso de los médicos del Colegio Americano , de cardiología 2020 , no dejes de leerlo!!! ACC Expert Consensus Dec…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @majedalhoriby: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants link : https:/…
Release the tax returns
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants link : https://t.co/8AxBPFtNcj https://t.co/fVT8vQQFYO
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
2020 ACC - Expert Consensus Decision Pathway on Management of #Bleeding in Patients on #OralAnticoagulants: A Report of the #AmericanCollegeCardiology Solution Set Oversight Committee https://t.co/yjyKfavtFW
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @MayaHolsen: Reverse, reverse! ⏮‼️🆘🛑 New guidance: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on…
Read up! 💊🩸💉 https://t.co/bHV2KVeuCM
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @MayaHolsen: Reverse, reverse! ⏮‼️🆘🛑 New guidance: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on…
RT @SnayCardsPharmD: Updated consensus statement on managing bleeding in patients taking DOACs or Warfarin. 2020 ACC Expert Consensus Dec…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @rincondesisifo: (JACC) Abordaje de la hemorragia en pac anticoagulados https://t.co/HezhmzYZQF Consenso de expertos https://t.co/k6RSuM…
RT @iK2NAN: New guidance 2020 : Management of Bleeding in Patients on Oral Anticoagulants | JACC : Journal of the American College of Card…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
Andexxa getting firm recommendations from American College of Cardiology. Not long $ALXN $PTLA take over, $ALXN going to ramp sales for this drug after all?
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @MayaHolsen: Reverse, reverse! ⏮‼️🆘🛑 New guidance: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on…
RT @MayaHolsen: Reverse, reverse! ⏮‼️🆘🛑 New guidance: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on…
There are too many unanswered questions about sustained efficacy for me to take this seriously.
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
This gonna be spicy.
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @MayaHolsen: Reverse, reverse! ⏮‼️🆘🛑 New guidance: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @renalpages: Long but really clear #decisionaid on mx of bleeding of patients on oral #anticoagulants from @ACCinTouch https://t.co/9H…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
New guidance 2020 : Management of Bleeding in Patients on Oral Anticoagulants | JACC : Journal of the American College of Cardiology. https://t.co/rtQ5zonx3z https://t.co/jldkhzExmI
Had high hopes this wouldn’t be the case but alas...😓
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
RT @PharmERToxGuy: Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 p…
Andexanet getting too much love for being a costly, flawed antidote w/ the 'supporting' evidence coming largely from 1 prospective observational study 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
RT @notthewongrx: Thx to @SnayCardsPharmD for pointing out updated 2020 @JACCJournals Consensus on mgmt of bleeding from OAC (VKA, DOACs).…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @notthewongrx: Thx to @SnayCardsPharmD for pointing out updated 2020 @JACCJournals Consensus on mgmt of bleeding from OAC (VKA, DOACs).…
@ArielFretes4
RT @notthewongrx: Thx to @SnayCardsPharmD for pointing out updated 2020 @JACCJournals Consensus on mgmt of bleeding from OAC (VKA, DOACs).…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @renalpages: Long but really clear #decisionaid on mx of bleeding of patients on oral #anticoagulants from @ACCinTouch https://t.co/9H…
Long but really clear #decisionaid on mx of bleeding of patients on oral #anticoagulants from @ACCinTouch https://t.co/9H5EjkseOJ @Paneeshas @bloodmed @manosnikolousis - is Haris on Twitter ? https://t.co/xrKV02Y4Vk
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @Ed_Alania: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants via @JACCJournals #C…
RT @cpcannon: Excellent guide for management of bleeding for patients on NOACs or warfarin https://t.co/V5bROhxFYt